AAV Vectors Targeted to the Central Nervous System
AssigneeThe University of North Carolina at Chapel Hill
InventorsSteven Gray, Thomas McCown
Life of this patent
Estimating the term…
Abstract
The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.
Claims29
A nucleic acid encoding an AAV capsid, the nucleic acid comprising an AAV capsid coding sequence that is at least 70% identical to:
- (a) the nucleotide sequence of any one of SEQ ID NOS:1-43;
- or
- (b) a nucleotide sequence encoding any one of SEQ ID NOS:44-86.
2-5. (canceled)
A nucleic acid encoding an AAV capsid, the nucleic acid comprising a VP1, VP2, or VP1/VP2 encoding portion of an AAV capsid coding sequence that is at least 70% identical to:
- (a) the nucleotide sequence of any one of SEQ ID NOS:1-43;
- or
- (b) a nucleotide sequence encoding any one of SEQ ID NOS:44-86;
- operably linked to a VP3 encoding portion of a different AAV capsid coding sequence.
7-11. (canceled)
(canceled)
An AAV capsid comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOS:44-86.
18-20. (canceled)
An AAV capsid comprising a VP1, VP2, or VP1/VP2 portion comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOS:44-86;
- operably linked to a VP3 portion of a different AAV capsid.
22-24. (canceled)
28-33. (canceled)
(canceled)
42-45. (canceled)
48-171. (canceled)
Dependencies are inferred from the claim text.